LBA6 PACIFIC-5: A phase III study of consolidation durvalumab (D) in patients (pts) with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy (cCRT or sCRT)
Yi‐Long Wu(Guangdong Academy of Medical Sciences), Lin Wang(The Synergetic Innovation Center for Advanced Materials), Yue Yang(AstraZeneca (Germany)), Zhenggang Zhu(Wuhan Center for Disease Control and Prevention), Richeng Mao(Fudan University), Lihong Wu(Hunan Cancer Hospital), Mehmet Alı Nahıt Şendur(Ankara Yıldırım Beyazıt University), Maciej Krzakowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Tulin Cil(University Health Network), Daojun Lv(Third Affiliated Hospital of Guangzhou Medical University), Mustafa Dikilitaş(Inonu University), Bing Zhang(Baylor College of Medicine), Yonglong Pan(Tongji Hospital), Jian Sun(Army Medical University), YC Kim(Chonnam National University Hwasun Hospital), M. E(Harbin Medical University), N. Bi(Chinese Academy of Medical Sciences & Peking Union Medical College), W. Zhang(Tongji University), Hang Ge(Heilongjiang University of Chinese Medicine), Chung‐Li Wang(Chang Gung Memorial Hospital)
Cited by 8
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k